Technical Analysis for SLRN - Acelyrin Inc.

Grade Last Price % Change Price Change
D 17.60 3.71% 0.63
SLRN closed up 3.71 percent on Thursday, June 8, 2023, on 83 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Down

Date Alert Name Type % Chg
Stochastic Buy Signal Bullish 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 3.71%
Hot IPO Pullback Bullish Swing Setup 3.71%
Doji - Bullish? Reversal 3.71%
New 52 Week Low Weakness 3.71%
Outside Day Range Expansion 3.71%
Wide Bands Range Expansion 3.71%
Oversold Stochastic Weakness 3.71%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Hot IPO Pullback Entry about 11 hours ago
Rose Above Previous Day's High about 11 hours ago
60 Minute Opening Range Breakout about 12 hours ago
Up 3% about 14 hours ago
1.5x Volume Pace about 14 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Acelyrin Inc. Description

ACELYRIN, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Medicine Drugs Monoclonal Antibodies Uveitis Psoriatic Arthritis Hidradenitis Suppurativa Thyroid Eye Disease Chronic Urticaria Duligotuzumab

Is SLRN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 25.84
52 Week Low 16.6
Average Volume 715,673
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 19.97
10-Day Moving Average 17.96
Average True Range 1.58
RSI (14) 32.43
ADX 0.0
+DI 9.45
-DI 25.99
Chandelier Exit (Long, 3 ATRs) 21.10
Chandelier Exit (Short, 3 ATRs) 21.34
Upper Bollinger Bands 24.60
Lower Bollinger Band 15.34
Percent B (%b) 0.24
BandWidth 46.36
MACD Line -2.16
MACD Signal Line -1.61
MACD Histogram -0.5444
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.92
Resistance 3 (R3) 18.82 18.28 18.70
Resistance 2 (R2) 18.28 17.94 18.33 18.63
Resistance 1 (R1) 17.94 17.74 18.11 18.04 18.55
Pivot Point 17.40 17.40 17.49 17.45 17.40
Support 1 (S1) 17.06 17.06 17.23 17.16 16.65
Support 2 (S2) 16.52 16.86 16.57 16.57
Support 3 (S3) 16.18 16.52 16.50
Support 4 (S4) 16.28